logo

HomeArticlesServicePriceAbout

EN

Menu

Home
Articles
Search
About
EN
logo
Price
logo

Company

AboutTerms of Service Privacy Policy

Social

LinkedIn Twitter Discord

Contact

contact@coresixteen.com coresixteen.com
Company NameCORE16 Inc.
CEODavid Cho
Business Registration Number762-81-03235
Address83, Uisadang-daero, Yeongdeungpo-gu, Seoul, 07325, Republic of KOREA
Pfizer
Search Result
Firm
user
셀스마트 대니
·
3 months ago
0
0
📢 S&P 500 Stocks with Downgraded Ratings (4th Week of March) 📢
article
Strong Sell
Strong Sell
PFE
Pfizer
+2
user
셀스마트 대니
·
3 months ago
0
0
📢 S&P 500 Stocks with Downgraded Ratings (4th Week of March) 📢
Over the past 4 weeks (from Feb 21 to Mar 21, 2025), several S&P 500 constituents have seen their analyst ratings downgraded, reflecting shifts in company fundamentals, macroeconomic headwinds, and evolving competitive dynamics within industries.From a short-selling perspective, these rating downgrades may indicate rising short-term downside pressure on the respective stocks. Investors should consider prudent risk management and tactical positioning.Below is a summary of the stocks with the most significant downgrades in analyst ratings, including their previous and current scores, and the degree of change:1. Arch Capital (ACGL-US)Rating (Feb 21, 2025): 0.0Rating (Mar 21, 2025): 4.0Change: -4.0Key Issue: Growing risks in the insurance and reinsurance markets, coupled with declining investment returns, are dampening the company’s growth outlook.2. Pfizer (PFE-US)Rating (Feb 21, 2025): 0.0Rating (Mar 21, 2025): 3.5Change: -3.5Key Issue: Waning demand for COVID-19 vaccines and therapeutics, along with uncertainty surrounding its drug pipeline, are weighing on earnings expectations.3. TE Connectivity (TEL-US)Rating (Feb 21, 2025): 0.0Rating (Mar 21, 2025): 3.7Change: -3.7Key Issue: Weakening demand for automotive and industrial electronic components, as well as ongoing global supply chain disruptions, are constraining the company’s earnings growth potential.Broader Context & TakeawaysWhile each downgrade has distinct drivers, the overarching themes include recession concerns, supply chain instability, rising costs, and intensifying competition. In some cases, sector-specific structural shifts—such as fluctuations in EV battery demand or semiconductor cycles—have also played a major role.From a short strategy perspective, these names may exhibit downward price momentum in the near term. Investors may consider trimming exposure or exploring tactical short opportunities. With earnings season, interest rate decisions, and macro data releases approaching, volatility could spike, making adaptive positioning all the more critical.[Compliance Note]All posts by Sellsmart are for informational purposes only. Final investment decisions should be made with careful judgment and at the investor’s own risk.The content of this post may be inaccurate, and any profits or losses resulting from trades are solely the responsibility of the investor.Core16 may hold positions in the stocks mentioned in this post and may buy or sell them at any time.
article
Strong Sell
Strong Sell
PFE
Pfizer
+2
user
박재훈투영인
·
4 months ago
0
0
It looks like Santa Claus is on his way to stock investors in the week ahead(Dec 26, 2021)
article
Sell
Sell
226490
Samsung KODEX KOSPI ETF
user
박재훈투영인
·
4 months ago
0
0
It looks like Santa Claus is on his way to stock investors in the week ahead(Dec 26, 2021)
After a period of turbulence, the decks may be cleared for a good old-fashioned Santa Claus rally in the week ahead.Stocks were higher in the past week, after a rough stretch that continued into Monday. The S&P 500 recovered and is up about 3.5% for December as of Thursday.“I think all the things we’ve been concerned about for the month of December to a certain extent, are in the rearview mirror,” said Art Hogan, chief market strategist at National Securities. “We know what the [Federal Reserve] is going to do. We know while this new variant spreads faster, it’s not as dangerous, and we know Build Back Better legislation is now 2022′s business... I think the market can find a path of least resistance to the upside as we wrap things up.”The market has a lot of history on its side that trading days before the year-end are positive for stocks. According to the “Stock Trader’s Almanac,” the Santa Claus rally period — the final five trading days of the current year and first two of the new year — is mostly a time when the stock market gains. The S&P 500 has been positive nearly 79% of the time on those days since 1928 and has gained an average of about 1.7% per rally.Add to that the fact that when the market has had a strong year, the momentum historically has carried into the final trading sessions. In that regard, the S&P 500 is up about 25% for the year.According to Bank of America, when the S&P 500 has already seen such solid gains, the final six sessions are positive. Since 1980, there have been 10 instances where the S&P 500 was up 20% or more going into the last stretch of trading and in nine of those years, it ended the final six days higher.A notably rocky DecemberStocks head into the final sessions of the year with a tailwind, after several weeks of choppiness.“This has been the fourth rockiest December since 1987. The average daily move for the S&P 500 has been 1.1%,” said Hogan. “That’s a lot of action.” The most volatile Decembers were in 2000, 2008 and 2018.Hogan said volume in the last week of the year is typically 20% to 30% lower than normal. “In a low-volume environment, when the market picks a direction, it tends to move in that direction in a robust fashion,” he said.Paul Hickey, co-founder of Bespoke Investment Group, said positive news on the Covid omicron variant this week was the catalyst that reversed the market’s sell-off. There were studies showing omicron to be milder than other variants of the coronavirus. Further, the Food and Drug Administration approved pills from Pfizer and Merck for the treatment of Covid-19.“Whereas the market was focusing on everything that could go wrong since Thanksgiving, people are now just taking a sunnier view,” Hickey said. He expects that view will likely prevail in the coming week.“As we get toward the beginning of January, we’ll see how markets are positioning themselves,” Hickey said. He said investors will start to turn their attention toward the upcoming earnings season; they do not seem to be overly optimistic, which could spell some upside surprises.“Going into the last earnings season, there was a ton of negative sentiment based on supply chains, inflation and labor shortages. We ended up having a decent earnings season. It’s more mixed this time,” Hickey said.High-growth stocks hitThe selling in November and December dented stocks. Some high-growth stocks and ETFs were down sharply as investors moved into safety plays. Funds that took their lumps in December include the Ark Innovation ETF and iShares Expanded Tech Software Sector ETF.“I think some of these growth areas that have gotten hit hard will do a little better. They could see a bounce early in the year,” Hickey said. “They sold off for a number of reasons. One was concerns over the Fed. Also people had made so much money, and the feeling was taxes are going up. People were selling stocks ahead of higher taxes. That’s more of a question now with a divided Congress.”
article
Sell
Sell
226490
Samsung KODEX KOSPI ETF
Economy & Strategy
user
박재훈투영인
·
4 months ago
0
0
Healthcare Stocks in the Trump Era: What Should Investors Do? (Nov 20, 2024)
article
Sell
Sell
453640
KODEX S&P500 Health Care
user
박재훈투영인
·
4 months ago
0
0
Healthcare Stocks in the Trump Era: What Should Investors Do? (Nov 20, 2024)
A photo of Robert F. Kennedy Jr. sharing a McDonald’s meal with Donald Trump aboard Trump Force One has sparked early contradictions in the administration’s "Make America Healthy Again" agenda.Donald Trump Jr. shared the image on X, joking, "Making America healthy starts tomorrow." While it's unfair to criticize Kennedy for enjoying fries and cola, the image highlights the paradox of a vaccine-skeptic health advocate dining with a fast-food enthusiast—the very man who once boasted about accelerating COVID-19 vaccine development.Potential Conflicts in Healthcare PolicyKennedy’s anti-corporate stance—particularly against Big Pharma—is more aligned with left-wing populism than Trump’s pro-business policies. While Trump prioritizes tax cuts and tariffs, he has lacked a consistent healthcare reform agenda. His previous attempts to reshape drug pricing and overhaul Obamacare were largely abandoned.Kennedy’s nomination as Secretary of Health and Human Services (HHS) could bring significant regulatory uncertainty for the pharmaceutical industry. His calls for stricter FDA oversight over major drug companies stand in stark contrast to Trump’s deregulatory agenda—a divide already evident within Trump's camp.For instance, Vivek Ramaswamy, a biotech investor and Trump ally, argues that the FDA is overly restrictive and hinders innovation. If Ramaswamy influences Trump’s decisions, it could lead to FDA deregulation, favoring pharmaceutical companies. The key question remains: Will Trump align with Kennedy's aggressive stance on Big Pharma, or will he side with the industry and Wall Street?Market Reactions & Investor ConcernsHealthcare stocks plunged following Kennedy's nominationNYSE Arca Pharmaceutical Index: -5%SPDR S&P Biotech ETF: -10%Big Pharma stocks are already trading at a discountCurrently priced ~35% below the S&P 500Excluding Eli Lilly, the discount rises to 45-50%Uncertainty looms over Kennedy’s actual influenceHHS oversees the FDA, NIH, and CDC, impacting over 80,000 employeesKennedy has advocated caps on drug prices and tighter restrictions on pharmaceutical ads—policies viewed as worst-case scenarios for the industryDespite these concerns, Kennedy may struggle to enact sweeping regulatory changes due to the sheer bureaucratic complexity of the FDA. According to BMO Capital Markets analyst Evan Seigerman, Trump is likely to appoint an industry-friendly FDA chief—just as he did in his first term with former Pfizer board member Scott Gottlieb.Long-Term ImplicationsInvestors should temper expectations for radical healthcare reforms.Trump’s first term showed that healthcare reform is a slow, complex process requiring bipartisan compromise.Kennedy’s opposition to obesity drugs (GLP-1 treatments) could backfire politically, limiting his ability to push through drastic policy changes.Trump may roll back Biden’s Medicare drug pricing negotiation policy, providing relief to pharmaceutical firms.The potential removal of FTC Chair Lina Khan—a critic of Big Pharma—could open the door for more biotech M&A activity.[Compliance Note]All posts by Sellsmart are for informational purposes only. Final investment decisions should be made with careful judgment and at the investor’s own risk.The content of this post may be inaccurate, and any profits or losses resulting from trades are solely the responsibility of the investor.Core16 may hold positions in the stocks mentioned in this post and may buy or sell them at any time.
article
Sell
Sell
453640
KODEX S&P500 Health Care